Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Sodium Phosphate, Monobasic is an inorganic salt used primarily as an osmotic laxative, a urinary acidifier, and a source of phosphorus in electrolyte replacement therapies. It functions by increasing fluid in the small intestine and acting as a physiological buffer.
Name
Sodium Phosphate, Monobasic, Unspecified Form
Raw Name
SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM
Category
Other
Drug Count
16
Variant Count
17
Last Verified
February 17, 2026
RxCUI
283100, 1604338
UNII
GR686LBA74, 3980JIH2SW
About Sodium Phosphate, Monobasic, Unspecified Form
Sodium Phosphate, Monobasic is an inorganic salt used primarily as an osmotic laxative, a urinary acidifier, and a source of phosphorus in electrolyte replacement therapies. It functions by increasing fluid in the small intestine and acting as a physiological buffer.
Detailed information about Sodium Phosphate, Monobasic, Unspecified Form
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Sodium Phosphate, Monobasic, Unspecified Form.
Sodium Phosphate, Monobasic (chemical formula NaH2PO4) is an inorganic compound consisting of a sodium cation and a dihydrogen phosphate anion. In clinical pharmacology, it is categorized primarily as an osmotic laxative and an electrolyte replenisher. It belongs to the broader class of medications known as saline laxatives or phosphorus supplements, depending on its clinical application. This 'unspecified form' designation typically refers to the active moiety regardless of its hydration state (anhydrous, monohydrate, or dihydrate), all of which provide the essential phosphate ion (PO4^3-) required for numerous physiological processes.
Historically, sodium phosphates have been utilized in medicine for over a century. The FDA has regulated various formulations of sodium phosphate under different pathways, including the Over-the-Counter (OTC) Monograph for laxative use and the New Drug Application (NDA) process for high-dose bowel preparations used prior to colonoscopies. Sodium phosphate monobasic is frequently paired with sodium phosphate dibasic to create a buffered solution that maintains a specific pH, making it ideal for both oral and intravenous administration. In the context of modern medicine, it serves as a critical tool for managing phosphorus deficiency (hypophosphatemia), acidifying urine to prevent certain types of kidney stones, and ensuring clear visualization during diagnostic intestinal procedures.
At the molecular level, the mechanism of action for Sodium Phosphate, Monobasic depends heavily on its route of administration and the intended therapeutic goal. When used as an osmotic laxative, the phosphate ions are poorly absorbed by the epithelial lining of the gastrointestinal tract. According to the principles of osmosis, these ions create a high solute concentration within the intestinal lumen. To reach equilibrium, the body draws significant amounts of water from the surrounding tissues into the bowel. This increase in intraluminal fluid volume exerts mechanical pressure on the intestinal walls, stimulating peristalsis (the rhythmic contraction of the gut) and promoting a rapid, watery bowel movement.
When utilized for electrolyte replacement, the drug provides a direct source of inorganic phosphorus. Phosphorus is the second most abundant mineral in the human body and is vital for the formation of adenosine triphosphate (ATP), the primary energy currency of cells. It is also a structural component of phospholipids in cell membranes and hydroxyapatite in bone tissue. Furthermore, as a urinary acidifier, the monobasic form (which is acidic) increases the excretion of hydrogen ions in the renal tubules. This lowers the pH of the urine, which can enhance the effectiveness of certain antibiotics (like methenamine) and help dissolve or prevent the formation of alkaline-based urinary calculi (stones).
Healthcare providers typically utilize Sodium Phosphate, Monobasic for the following FDA-approved and clinically accepted indications:
Sodium Phosphate, Monobasic is available in several delivery formats to suit different clinical needs:
> Important: Only your healthcare provider can determine if Sodium Phosphate, Monobasic, Unspecified Form is right for your specific condition. The choice of formulation depends on the urgency of the condition and the patient's underlying renal function.
The dosage of Sodium Phosphate, Monobasic varies significantly based on the indication. For bowel cleansing, a common regimen involves taking a total of 32 to 40 grams of sodium phosphate (in divided doses of tablets or solution) over several hours the night before and the morning of the procedure. For urinary acidification, healthcare providers may recommend 1 gram dissolved in water four times daily. For general phosphorus supplementation, doses are typically calculated in millimoles (mmol), with a standard range of 10 to 15 mmol taken two to three times daily, depending on serum phosphorus levels.
Pediatric use must be strictly supervised by a pediatrician. For children aged 5 to 11 years, rectal enemas are sometimes used at half the adult volume (approximately 60 mL). Oral sodium phosphate for bowel cleansing is generally not recommended for children under the age of 18 due to the high risk of electrolyte shifts and kidney injury. For phosphorus supplementation in infants and children, the dose is highly individualized based on weight and the severity of the deficiency, often ranging from 0.5 to 1.5 mmol/kg per day.
Sodium Phosphate, Monobasic is primarily cleared by the kidneys. In patients with a Glomerular Filtration Rate (GFR) less than 60 mL/min/1.73m², extreme caution is required. High-dose bowel preparations are generally contraindicated in patients with significant renal impairment (Stage 3-5 Chronic Kidney Disease) due to the risk of acute phosphate nephropathy (permanent kidney damage caused by calcium-phosphate crystals).
No specific dosage adjustments are usually required for patients with liver disease, as the drug is not metabolized by the liver. However, patients with cirrhosis and ascites may be sensitive to the sodium load contained in these preparations and should be monitored for fluid retention.
Patients over the age of 65 are at a higher risk for dehydration and electrolyte imbalances. Healthcare providers often recommend lower initial doses and emphasize aggressive hydration during the use of sodium phosphate products.
When taking oral formulations for bowel prep, it is critical to follow a 'clear liquid diet' as instructed by your clinic. The medication should be taken with at least 8 ounces of water or a clear beverage. For tablets, they must be swallowed whole; do not crush or chew them. When using the rectal enema, lie on your left side with knees bent, gently insert the nozzle, and squeeze the liquid into the rectum. Try to retain the fluid for 2 to 5 minutes or until a strong urge to defecate is felt. Store all forms at room temperature, away from excessive heat and moisture.
If you miss a dose of a daily supplement, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not double the dose. If you miss a dose during a bowel cleansing regimen, contact your doctor or the endoscopy center immediately, as the procedure may need to be rescheduled.
Signs of an overdose include severe nausea, persistent vomiting, abdominal cramps, seizures, or an irregular heartbeat (arrhythmia). These symptoms are often caused by dangerously high phosphate levels (hyperphosphatemia) or low calcium levels (hypocalcemia). If an overdose is suspected, seek emergency medical attention or contact a Poison Control Center immediately. Treatment typically involves intravenous fluids and medications to lower phosphate levels; in severe cases, dialysis may be required.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or the timing of your bowel prep without direct medical guidance, as this could lead to an incomplete procedure or serious health risks.
Most patients taking Sodium Phosphate, Monobasic for bowel cleansing will experience gastrointestinal effects. These are expected as part of the drug's action but can be uncomfortable. Common symptoms include:
> Warning: Stop taking Sodium Phosphate, Monobasic, Unspecified Form and call your doctor immediately if you experience any of these serious symptoms:
Sodium Phosphate, Monobasic is rarely used long-term at high doses. However, chronic use as a laxative can lead to 'cathartic colon,' where the bowels become dependent on the medication to function. Long-term use for phosphorus supplementation requires regular monitoring to prevent the development of soft tissue calcification, where calcium and phosphate deposit in the heart, lungs, or joints.
The FDA has issued a Black Box Warning for certain oral sodium phosphate products (like OsmoPrep) regarding the risk of Acute Phosphate Nephropathy. This condition involves the deposition of calcium phosphate crystals in the renal tubules, which can lead to permanent loss of kidney function. Risk factors include being over age 55, dehydration, a history of kidney disease, and the use of certain medications like ACE inhibitors or NSAIDs. Patients must be screened for these risks before using high-dose oral sodium phosphate.
Report any unusual symptoms to your healthcare provider. Even mild symptoms can sometimes escalate if not addressed, particularly regarding hydration levels.
Sodium Phosphate, Monobasic is a potent osmotic agent. The most critical safety consideration is the maintenance of adequate hydration. Patients must drink clear liquids before, during, and after the use of this medication to prevent severe dehydration and kidney injury. It is not a 'simple' laxative and carries risks that are significantly higher than other osmotic agents like polyethylene glycol (PEG).
For patients at higher risk or those using the drug for supplementation, healthcare providers typically order the following lab tests:
While the drug itself does not cause sedation, the side effects of dehydration, dizziness, and the necessity of remaining near a bathroom make driving or operating heavy machinery inadvisable during the bowel preparation process.
Alcohol should be avoided while using Sodium Phosphate, Monobasic. Alcohol is a diuretic and can significantly worsen the dehydration caused by the laxative effect, increasing the risk of kidney damage.
For bowel prep, the medication is a one-time or two-time dose and is discontinued once the procedure is complete. For supplements, do not stop taking the medication suddenly if you have a chronic deficiency, as your phosphorus levels may drop dangerously low. Always consult your doctor before stopping a prescribed supplement.
> Important: Discuss all your medical conditions, especially any history of kidney, heart, or bowel disease, with your healthcare provider before starting Sodium Phosphate, Monobasic, Unspecified Form.
Sodium Phosphate, Monobasic should not be used with other sodium phosphate-containing laxatives (such as OTC Fleet Phospho-soda) simultaneously. Combining these products exponentially increases the risk of hyperphosphatemia and acute kidney injury. Additionally, it should not be used with Pimozide, as electrolyte shifts can increase the risk of QT prolongation and fatal heart rhythms.
Sodium Phosphate, Monobasic can temporarily affect several lab results:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those taken 'as needed' like ibuprofen.
Sodium Phosphate, Monobasic must NEVER be used in patients with the following conditions:
Healthcare providers must perform a careful risk-benefit analysis for patients with:
There is no known cross-sensitivity with non-phosphate medications. However, patients who have had a severe allergic reaction to any 'sodium phosphate' product (monobasic, dibasic, or tribasic) should avoid all forms of this inorganic salt.
> Important: Your healthcare provider will evaluate your complete medical history, including recent blood work, before prescribing Sodium Phosphate, Monobasic, Unspecified Form.
Sodium Phosphate, Monobasic is generally classified in FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. It is unknown whether the drug can cause fetal harm or affect reproduction capacity. Because pregnancy itself alters renal function and fluid balance, healthcare providers typically prefer other osmotic laxatives like polyethylene glycol (PEG) for bowel cleansing in pregnant patients. It should only be used if the potential benefit justifies the potential risk to the fetus.
It is not known whether Sodium Phosphate, Monobasic is excreted in human milk. However, because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants from the phosphate and sodium load, a decision should be made whether to discontinue nursing or to avoid the drug. If used, mothers may choose to pump and discard milk for 24 hours after the last dose.
Safety and effectiveness of oral sodium phosphate for bowel cleansing have not been established in patients under 18 years of age. Use in children is associated with a much higher risk of severe dehydration and 'water intoxication' (hyponatremia). Rectal enemas should only be used in children aged 2 and older under strict medical supervision. Death has been reported in children who received adult-strength enemas.
Patients over age 65 are at the highest risk for complications. Clinical studies have shown that elderly patients have a higher incidence of serious adverse events, including renal failure and arrhythmias, compared to younger patients. This is often due to age-related declines in GFR and a higher prevalence of comorbid conditions. Providers often recommend 'split-dose' regimens and extra hydration for this population.
As the kidneys are the sole route of phosphate excretion, any degree of renal impairment increases the half-life of the drug and the risk of crystal deposition. In patients with moderate renal impairment (GFR 30-60), the drug should be used with extreme caution, and baseline/follow-up electrolytes are mandatory.
While the liver does not metabolize this salt, patients with end-stage liver disease often have 'hepatorenal syndrome' or delicate fluid balances. The high sodium load in monobasic sodium phosphate can worsen ascites (fluid in the abdomen) or edema.
> Important: Special populations require individualized medical assessment and often more frequent monitoring of blood chemistry.
Sodium Phosphate, Monobasic acts as a saline osmotic laxative. In the small intestine, the phosphate ions are only partially absorbed. The unabsorbed ions exert an osmotic pressure that draws water into the intestinal lumen. This process is governed by the Van't Hoff equation for osmotic pressure. The resulting increase in fluid volume distends the cecum and colon, which activates stretch receptors in the enteric nervous system. This triggers the 'myenteric reflex,' increasing propulsive motility. As a supplement, the monobasic salt dissociates into Na+ and H2PO4-. The H2PO4- ion acts as a weak acid, contributing to the phosphate buffer system (H2PO4- <-> HPO4^2- + H+), which is the primary buffer in the intracellular fluid and the renal tubules.
The dose-response relationship is well-characterized: higher doses lead to more rapid and voluminous bowel movements. The onset of action for oral administration is typically 30 minutes to 3 hours. For rectal administration, the onset is 2 to 5 minutes. The duration of effect lasts until the osmotic load has been cleared from the bowel, usually 4 to 6 hours. Tolerance does not typically develop with acute use, but chronic use can lead to a loss of normal colonic tone.
| Parameter | Value |
|---|---|
| Bioavailability | 40% - 70% (as phosphate) |
| Protein Binding | Negligible |
| Half-life | Variable (dependent on renal function) |
| Tmax | 1 - 3 hours (peak serum phosphate) |
| Metabolism | None (inorganic salt) |
| Excretion | Renal >90%, Fecal (unabsorbed portion) |
Sodium Phosphate, Monobasic is classified as a Saline Laxative and an Electrolyte Supplement. It is related to other phosphate salts like Sodium Phosphate Dibasic and Potassium Phosphate. Within the laxative category, it is considered more potent and carries more systemic risk than 'bulk-forming' laxatives (like psyllium) or 'stimulant' laxatives (like bisacodyl).
Common questions about Sodium Phosphate, Monobasic, Unspecified Form
Sodium Phosphate, Monobasic is primarily used as a powerful osmotic laxative to clear the bowels before medical procedures like colonoscopies. It is also used as a mineral supplement to treat low phosphorus levels in the blood and as a urinary acidifier to help certain antibiotics work better or prevent kidney stones. By drawing water into the intestines, it promotes rapid bowel movements, usually within a few hours. Because of its potency, it is often prescribed in specific, timed doses. Always use this medication under the guidance of a healthcare professional, especially when used for bowel preparation.
The most common side effects include abdominal bloating, nausea, stomach cramping, and frequent watery stools. These effects are generally expected when the drug is used for bowel cleansing as it works by drawing large amounts of water into the gut. Some patients may also experience a mild headache or dizziness, often due to the fluid shifts and fasting required for the procedure. While uncomfortable, these symptoms usually resolve once the bowel is empty. However, if vomiting becomes severe and you cannot keep the medication down, you should contact your doctor immediately. Maintaining hydration with clear liquids is essential to minimize these side effects.
No, you should strictly avoid alcohol while taking Sodium Phosphate, Monobasic, particularly during a bowel cleansing regimen. Alcohol acts as a diuretic, which means it encourages your body to lose even more fluid through urination. When combined with the significant fluid loss caused by the laxative, alcohol greatly increases your risk of severe dehydration and electrolyte imbalances. This combination can lead to serious complications, including fainting, heart rhythm problems, or even acute kidney injury. Stick to water, clear juices, or electrolyte-replacement sports drinks as recommended by your healthcare provider. Always wait until after your medical procedure and until you are fully rehydrated before consuming alcohol.
Sodium Phosphate, Monobasic is generally not the first choice for pregnant women and is categorized as FDA Pregnancy Category C. This means there is limited research on its effects in human pregnancy, and it should only be used if the potential benefits outweigh the risks to the fetus. Pregnancy can change how your kidneys handle minerals and fluids, making the electrolyte shifts caused by this drug more dangerous. Most doctors prefer safer alternatives like polyethylene glycol (PEG) for constipation or bowel prep during pregnancy. If you are pregnant or planning to become pregnant, discuss all options with your obstetrician before using this medication. It is vital to ensure that both the mother's and the baby's health are prioritized.
The onset of action depends on how the medication is administered. When taken orally as a solution or tablet, it typically begins to produce bowel movements within 30 minutes to 3 hours. When used as a rectal enema, the effect is much faster, usually occurring within 2 to 5 minutes. Because the oral form can work quickly and cause frequent bathroom visits, it is important to stay near a toilet once you have taken the dose. The total cleansing process for a colonoscopy usually lasts several hours. If you do not have a bowel movement within 6 hours of taking the oral dose, you should contact your healthcare provider.
If you are using Sodium Phosphate, Monobasic as a one-time bowel prep, you simply complete the prescribed doses and then stop. However, if you are taking it as a daily phosphorus supplement for a chronic condition, you should not stop taking it suddenly without consulting your doctor. Abruptly stopping a supplement can cause your blood phosphorus levels to drop, which may lead to muscle weakness, bone pain, or confusion. If you are experiencing side effects that make you want to stop the medication, your doctor can help you taper the dose safely or switch you to a different form of supplementation. Always follow the specific schedule provided by your medical team.
If you miss a dose while performing a bowel prep for a surgery or colonoscopy, call your doctor or the endoscopy center immediately. Missing a dose during this process may mean your bowel will not be clean enough for the doctor to see clearly, and the procedure might need to be rescheduled. If you are taking it as a daily supplement, take the missed dose as soon as you remember. If it is almost time for your next scheduled dose, skip the missed one and continue with your normal routine. Never take two doses at once to make up for a missed one, as this can cause dangerously high phosphate levels in your blood.
Sodium Phosphate, Monobasic does not cause long-term weight gain. In fact, when used as a bowel prep, most patients experience a temporary decrease in weight due to the loss of fluid and stool from the body. However, because the medication contains a significant amount of sodium, some patients with heart or kidney problems might experience temporary water retention or swelling (edema), which can look like weight gain on a scale. This is not an increase in body fat but a shift in fluid balance. If you notice sudden swelling in your ankles or shortness of breath after taking this medication, you should contact a healthcare provider immediately, as it could indicate a strain on your heart.
Sodium Phosphate, Monobasic has several significant drug interactions and should be used cautiously with other medicines. It is particularly dangerous to mix with blood pressure medications like ACE inhibitors (e.g., lisinopril) or ARBs (e.g., losartan), and common pain relievers like ibuprofen (Advil) or naproxen (Aleve), as these combinations significantly increase the risk of kidney failure. It can also interfere with the absorption of other oral medications because it speeds up the time it takes for things to pass through your system. Generally, you should take other medications at least 2 hours before or after taking sodium phosphate. Always provide your doctor with a full list of your current medications before starting this drug.
Yes, Sodium Phosphate, Monobasic is available as a generic medication and is also found in many over-the-counter products, such as Fleet Enemas and various generic saline laxatives. Generic versions are required by the FDA to have the same active ingredients and strength as brand-name versions. While the active ingredient is the same, different brands may have different flavors or inactive ingredients. For high-dose bowel preparations, you may be prescribed a specific brand-name kit (like OsmoPrep), but many hospital systems use generic versions for electrolyte replacement. Check with your pharmacist to see which version is most cost-effective for your specific needs.